An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new report from Epic Systems, a company that organizes lots of health records, says prescriptions for GLP-1 drugs have roughly quadrupled since 2021 while recorded obesity rates have fallen during the same period. In plain terms: many more people are getting prescriptions for this class of drugs now than a few years ago, and the data show a dip in obesity diagnoses that lines up with that rise. GLP-1 drugs are a group of medicines that copy a natural hormone called glucagon-like peptide-1. That hormone helps control blood sugar and also tells your body you’re full. The best-known names people have heard are semaglutide (sold as Ozempic or Wegovy) and tirzepatide (brand names vary). These are prescription injections that slow stomach emptying and reduce appetite, which often leads to weight loss in people who take them. What the Epic report actually shows is a correlation — prescriptions for GLP-1s went up a lot, and obesity diagnoses in the electronic records Epic examined went down. The story does not prove the drugs caused the drop in obesity. Epic’s data cover many health systems, which makes the trend notable, but it’s observational: it’s based on medical records, not a controlled experiment that isolates cause and effect. The report also doesn’t say how much weight individual patients lost, who started the drugs (diabetes patients, people with obesity, or others), or how long the effects lasted. Why this matters to regular people is straightforward. GLP-1 medicines are changing medical practice: more doctors are prescribing them, and more patients are using them for diabetes and weight management. That could mean better health outcomes for people with hard-to-manage weight and type 2 diabetes. It also affects costs and access: higher demand can lead to shortages, higher prices, and harder-to-get appointments or supplies. Employers, insurers, and health systems are paying attention because shifts in prescriptions change budgets and patient care patterns. There are important caveats and risks. These drugs have side effects like nausea, diarrhea, and rarely more serious problems such as pancreatitis (inflammation of the pancreas). Long-term safety and what happens after people stop the drugs are still being studied. Not everyone should use them—pregnant people, for example, are typically advised not to take GLP-1s. Also, a drop in recorded obesity in health records might reflect who’s getting seen by doctors or changes in how diagnoses are coded, not a true population-wide change. Finally, these medications require a prescription and medical supervision. Bottom line: GLP-1 prescriptions have surged and recorded obesity diagnoses have fallen in the same data set, which is an important trend but not definitive proof that the drugs alone caused the drop.
Source: Epic Systems